Clinical Trial

Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a multi-center, open label, phase Ib/II clinical trial aimed at evaluating the safety, preliminary efficacy characteristic and PK characteristics of QLS1304 in combined with endocrine therapy in ER+/HER2- breast cancer patients. This study was divided into two stages: combo dose escalation and dose expansion.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-14; most recent amendment 2026-05-21.
Status change: Not Yet Recruiting → Recruiting 2026-01-09
Trial Details
NCT Number NCT07235176
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Advanced ER+/HER2- Breast Cancer
Enrollment 300 participants
Start Date 2026-01-16
Primary Completion 2028-11-02 (estimated)
Study Completion 2031-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-22